Cinacalcet rectifies hypercalcemia in a patient with familial hypocalciuric hypercalcemia type 2 (FHH2) caused by a germline loss-of-function G11 mutation
Journal of Bone and Mineral Research Sep 04, 2017
Gorvin CM, et al. – Researchers aimed to present a novel heterozygous Gα11 germline mutation, Phe220Ser, which was associated with hypercalcemia in a family with familial hypocalciuric hypercalcemia type 2 (FHH2). The outcomes of this study display the importance of the Gα11 hydrophobic cleft region for calcium–sensing receptor (CaSR)–mediated activation of phospholipase C (PLC), and show that allosteric CaSR modulation can rectify the loss–of–function Phe220Ser mutation and ameliorate the hypercalcemia associated with FHH2.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries